Halozyme Therapeutics reported $23.02M in Cost of Sales for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
Acadia Pharmaceuticals ACAD:US $ 5.21M 0.51M
Alnylam Pharmaceuticals ALNY:US $ 30.26M 7.23M
Amarin AMRN:US $ 32.16M 3.83M
Amgen AMGN:US $ 1637M 147M
Baxter International BAX:US $ 1856M 75M
Eli Lilly And LLY:US $ 1953.2M 74.6M
Esperion Therapeutics ESPR:US $ 1.8M 16K
Halozyme Therapeutics HALO:US $ 23.02M 4.8M
Intercept Pharmaceuticals ICPT:US $ 0.62M 0.19M
Intra Cellular Therapies ITCI:US $ 2.04M 0.58M
Intrexon XON:US $ 15.03M 2.06M
JAZZ PHA JAZZ:US $ 119.19M 79M
Mannkind MNKD:US $ 9.93M 2.32M
Nektar Therapeutics NKTR:US $ 7.67M 1.91M
Peregrine Pharmaceuticals PPHM:US $ 19.36M 0.1M
Pfizer PFE:US $ 6992M 2820M
Rigel Pharmaceuticals RIGL:US $ 0.13M 0.19M
United Therapeutics UTHR:US $ 37.2M 14.2M
Vanda Pharmaceuticals VNDA:US $ 6.57M 0.54M